BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1642 related articles for article (PubMed ID: 27910859)

  • 1. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
    Li J; Yuan S; Norgard RJ; Yan F; Sun YH; Kim IK; Merrell AJ; Sela Y; Jiang Y; Bhanu NV; Garcia BA; Vonderheide RH; Blanco A; Stanger BZ
    Cancer Discov; 2021 Mar; 11(3):736-753. PubMed ID: 33158848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
    Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
    J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
    Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
    Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
    Kajihara M; Takakura K; Kanai T; Ito Z; Matsumoto Y; Shimodaira S; Okamoto M; Ohkusa T; Koido S
    World J Gastroenterol; 2016 May; 22(18):4446-58. PubMed ID: 27182156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VentX expression in tumor-associated macrophages promotes phagocytosis and immunity against pancreatic cancers.
    Le Y; Gao H; Richards W; Zhao L; Bleday R; Clancy T; Zhu Z
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
    Soares KC; Rucki AA; Wu AA; Olino K; Xiao Q; Chai Y; Wamwea A; Bigelow E; Lutz E; Liu L; Yao S; Anders RA; Laheru D; Wolfgang CL; Edil BH; Schulick RD; Jaffee EM; Zheng L
    J Immunother; 2015 Jan; 38(1):1-11. PubMed ID: 25415283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy.
    Oyama Y; Onishi H; Koga S; Murahashi M; Ichimiya S; Nakayama K; Fujimura A; Kawamoto M; Imaizumi A; Umebayashi M; Ohuchida K; Morisaki T; Nakamura M
    J Immunother; 2020 May; 43(4):121-133. PubMed ID: 31834207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
    Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
    Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma.
    Daley D; Mani VR; Mohan N; Akkad N; Pandian GSDB; Savadkar S; Lee KB; Torres-Hernandez A; Aykut B; Diskin B; Wang W; Farooq MS; Mahmud AI; Werba G; Morales EJ; Lall S; Wadowski BJ; Rubin AG; Berman ME; Narayanan R; Hundeyin M; Miller G
    J Exp Med; 2017 Jun; 214(6):1711-1724. PubMed ID: 28442553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer.
    Kemp SB; Pasca di Magliano M; Crawford HC
    Cell Mol Gastroenterol Hepatol; 2021; 12(5):1531-1542. PubMed ID: 34303882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
    Taube JM; Young GD; McMiller TL; Chen S; Salas JT; Pritchard TS; Xu H; Meeker AK; Fan J; Cheadle C; Berger AE; Pardoll DM; Topalian SL
    Clin Cancer Res; 2015 Sep; 21(17):3969-76. PubMed ID: 25944800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.
    Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY
    Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.